Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor

Edit Stockhouse 10 Nov 2016
Lane is a Professor of Dermatology and Pediatrics (Emeritus) at Stanford University School of Medicine and the former Chair of the Department of Dermatology where he led a research team focused on developing gene therapy for Epidermolysis Bullosa (EB) and other genetic skin diseases ... In addition, he is a Professor of Dermatology and Pediatrics (Emeritus) and is affiliated with Lucile Packard Children’s Hospital at Stanford....

Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor (Fibrocell Science Inc)

Edit Public Technologies 10 Nov 2016
Lane is a Professor of Dermatology and Pediatrics (Emeritus) at Stanford University School of Medicine and the former Chair of the Department of Dermatology where he led a research team focused on developing gene therapy for Epidermolysis Bullosa (EB) and other genetic skin diseases ... In addition, he is a Professor of Dermatology and Pediatrics (Emeritus) and is affiliated with Lucile Packard Children's Hospital at Stanford....

New drug clears atopic dermatitis in clinical trials (Northwestern University)

Edit Public Technologies 10 Nov 2016
(Source. Northwestern University). Jonathan Silverberg, MD, PhD, MPH, assistant professor of Dermatology, was a principal investigator of the phase III trials that tested a new drug for atopic dermatitis ... Jonathan Silverberg, MD, PhD, MPH, assistant professor of Dermatology, was a principal investigator of the studies ... Amy Paller, MD, chair of Dermatology, will be the principal investigator in those studies, with Ann & Robert H ... (noodl....

Foamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17 (Foamix Pharmaceuticals Ltd)

Edit Public Technologies 10 Nov 2016
(Source. Foamix Pharmaceuticals Ltd) ... (NASDAQ. FOMX), ('Foamix'), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr ... Date. ... Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions....

Foamix Pharmaceuticals to Present at Jefferies London Healthcare Conference on November 17

Edit PR Newswire 10 Nov 2016
REHOVOT, Israel and BRIDGEWATER, New Jersey, Nov. 10, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ. FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, ... ....

BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar

Edit PR Newswire 10 Nov 2016
MENLO PARK, Calif., Nov. 10, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT. BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present results from two clinical studies comparing oral and topical minocycline during a poster presentation ... ....

Galderma to Share Data from Phase 3 Studies of New Investigational Restylane® Refyne and Restylane® ...

Edit PR Newswire 10 Nov 2016
NEW ORLEANS, Nov. 10, 2016 /PRNewswire/ -- Galderma, a global leader focused on medical solutions in skin health, will share data from two pivotal Phase 3 clinical studies investigating Restylane® Refyne and Restylane® Defyne at the 2016 American Society for Dermatologic Surgery (ASDS) Ann ... ....

RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead ...

Edit Nasdaq Globe Newswire 10 Nov 2016
pylori is an increasingly important human pathogen; It is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma ... pylori infection, regardless of ulcer status, a significantly broader indication than current standard treatments for H. pylori, which are typically indicated only for patients with active or recent history of duodenal ulcer disease....

Doctors fight myth about African-Americans and skin cancer

Edit Springfield News-Sun 10 Nov 2016
Dermatologists recommend people to check their skin once a month for signs of skin cancer and to see a dermatologist once a year. Skin cancer can be even more dangerous for African-Americans. Darker skin does not make people immune to the danger. Preston Lewis is a trainer, and he stays on the move ... Read more trending stories ... Tonya McLeod, Piedmont Plastic Surgery & Dermatology ... McLeod said ... Dr....

Synergy Pharmaceuticals to Present at Jefferies 2016 London Healthcare Conference (Synergy Pharmaceuticals Inc)

Edit Public Technologies 10 Nov 2016
(Source. Synergy Pharmaceuticals Inc). NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ.SGYP) today announced the company will present a corporate update at the Jefferies London Healthcare Conference on Wednesday, November 16, 2016 at 8.00 a.m. GMT ... About Synergy Pharmaceuticals Inc ... Dolcanatide is Synergy's second uroguanylin analog currently being explored for ulcerative colitis ... View source version on businesswire.com....

Cosmo announces successful outcome of phase III clinical trial for LuMeBlue™ (Cosmo Pharmaceuticals SpA)

Edit Public Technologies 10 Nov 2016
The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections ... the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Santarus/Salix/Valeant and in the Rest of the World to Ferring as Cortiment®....
×